Education
About Us
Working with TipRanks
Follow Us
Dyadic International (DYAI)
NASDAQ:DYAI
DYAI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.93 - $2.67
Previous CloseN/A
Volume131.09K
Average Volume (3M)51.49K
Market Cap
$39.35M
Enterprise Value$26.13M
Total Cash (Recent Filing)$2.39M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 08, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding29,589,370
10 Day Avg. Volume80,846
30 Day Avg. Volume51,493
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)12.40
Price to Cash Flow (P/CF)-51.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.66
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit28.31
Enterprise Value/Ebitda-9.36
Forecast
1Y Price Target
$6.00Price Target Upside344.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
---
Dyadic International News
PremiumCompany Announcements
Dyadic’s Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Dyadic International Reports Strong 2024 Revenue Growth
PremiumCompany Announcements
Dyadic International Secures $4.5M for Vaccine Development
PremiumCompany Announcements
Dyadic International Secures Grant for Antibody Development---
Ownership Overview
19.21% Insiders
3.51% Mutual Funds
10.16% Other Institutional Investors
64.40% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
DYAI FAQ
What was Dyadic International’s price range in the past 12 months?
Dyadic International lowest stock price was $0.93 and its highest was $2.67 in the past 12 months.
What is Dyadic International’s market cap?
Dyadic International’s market cap is $39.35M.
When is Dyadic International’s upcoming earnings report date?
Dyadic International’s upcoming earnings report date is May 08, 2025 which is in 40 days.
How were Dyadic International’s earnings last quarter?
Dyadic International released its earnings results on Mar 26, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.04 by -$0.01.
Is Dyadic International overvalued?
According to Wall Street analysts Dyadic International’s price is currently Undervalued.
Does Dyadic International pay dividends?
Dyadic International does not currently pay dividends.
What is Dyadic International’s EPS estimate?
Dyadic International’s EPS estimate is -0.04.
How many shares outstanding does Dyadic International have?
Dyadic International has 29,589,370 shares outstanding.
What happened to Dyadic International’s price movement after its last earnings report?
Dyadic International reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.04. Following the earnings report the stock price went up 1.504%.
Which hedge fund is a major shareholder of Dyadic International?
Currently, no hedge funds are holding shares in DYAI
---
Dyadic International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.00 (344.44% Upside)
$6.00 (344.44% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.82%
12-Months-Change
Fundamentals
Return on Equity
-114.42%
Trailing 12-Months
Asset Growth
16.75%
Trailing 12-Months
Company Description
Dyadic International
Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 platform and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, bi/tri-specific antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and collaboration with Syngene International Limited. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.
---
DYAI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Dyadic's strong revenue growth, successful strategic partnerships, and advancements in product development, marking significant progress towards commercialization. However, increased expenses and a delayed timeline for product launches present challenges. Overall, the call reflects a positive outlook with some caution due to timing and cost-related issues.Read More>---
DYAI Stock 12 Month Forecast
Average Price Target
$6.00
▲(344.44% Upside)
Technical Analysis
Best Analysts Covering DYAI
1 Year
1 Year Success Rate
1/13 ratings generated profit
1 Year Average Return
-29.58%
reiterated a buy rating 5 months ago
Copying Vernon Bernardino's trades and holding each position for 1 Year would result in 7.69% of your transactions generating a profit, with an average return of -29.58% per trade.
---